Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | LMNA | P02545 | 6/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7072943 | 0.88 | ALDH1A1 (0.41) | KDM4EALDH1A1LMNATSHRSMN1; SMN2 | |
| SCHEMBL7068041 | 0.86 | ALDH1A1 (0.44) | KDM4EALDH1A1LMNATSHRSMN1; SMN2 | |
| SCHEMBL7067916 | 0.86 | KDM4E (0.46) | KDM4EALDH1A1LMNATSHRSMN1; SMN2 | |
| SCHEMBL7073031 | 0.84 | ALDH1A1 (0.52) | KDM4EALDH1A1LMNATSHRSMN1; SMN2 | |
| SCHEMBL7073603 | 0.84 | KDM4E (0.43) | KDM4EALDH1A1LMNATSHRSMN1; SMN2 | |
| SCHEMBL7073634 | 0.83 | NQO1 (0.45) | LMNASMN1; SMN2MAPTHTTRAB9A | |
| SCHEMBL7070128 | 0.82 | KRAS (0.42) | KDM4EALDH1A1LMNATSHRSMN1; SMN2 | |
| SCHEMBL7184162 | 0.80 | MAOA (0.52) | KDM4EALDH1A1LMNATSHRSMN1; SMN2 | |
| SCHEMBL8876628 | 0.77 | ALDH1A1 (0.52) | KDM4EALDH1A1LMNATSHRSMN1; SMN2 | |
| SCHEMBL7073297 | 0.76 | MAOB (0.43) | KDM4EALDH1A1LMNATSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6620842-B2 | Chalcones | INDENA SPA (IT) | 2003-09-16 | — | — | US | disclosed |
| EP-1212315-B1 | NOVEL CHALCONES | INDENA SPA (IT) | 2003-03-26 | — | — | EP | disclosed |
| US-20030055056-A1 | For use as antitumor and immune suppressive agents, as inhibitors of proliferative cell growth and as prophylactic agents to inhibit and prevent cancer and non-malignant cell growth | INDENA S.P.A. (IT) | 2003-03-20 | — | — | US | disclosed |
| EP-1212315-A1 | NOVEL CHALCONES | INDENA S.p.A. (IT) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001017988-A1 | NOVEL CHALCONES | INDENA S.P.A. (IT) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055056-A1 | For use as antitumor and immune suppressive agents, as inhibitors of proliferative cell growth and as prophylactic agents to inhibit and prevent cancer and non-malignant cell growth | HDGF, MKI67, HPD | KDM4E 397/4885ALDH1A1 2113/4885LMNA 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.